*To the Editor:* We have read with great interest the articles by Llamas-Velasco et al[@bib1] and Marzano et al[@bib2] about the current controversy regarding coronavirus disease 2019 (COVID-19) vesicular exanthems and the role of herpesvirus in the etiology of these lesions. Llamas-Velasco et al[@bib1] report 3 cases of vesicular lesions in patients hospitalized with COVID-19, suggesting that complementary tests, such as Tzanck smear, virus culture, polymerase chain reaction (PCR), or skin biopsy should be performed to rule out other viral infections. Marzano and Genovese[@bib2] were not able to perform PCR tests in their previous study of varicella-like exanthem[@bib3] due to logistic reasons but also due to clinical presentation not being suggestive of varicella.

We previously conducted a prospective study of vesicular COVID-19 rashes, all with a positive nasopharyngeal swab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in our hospital from March 1 to April 20, 2020.[@bib4] Of a total of 53 patients, 15 were excluded because of an alternative herpes simplex/zoster clinical diagnosis (clinical data are summarized in [Table I](#tbl1){ref-type="table"} ). All 15 patients presented typical clinical lesions and symptoms of herpes simplex/zoster. Only 1 patient (6.7%) had a previous history of immunosuppression. Latency time between COVID-19 symptoms and herpetic lesions was variable (median, 16 days; range, 6-32 days). Despite performing PCR tests for SARS-CoV-2 from the content of the vesicles in only 3 patients, all of the results were negative.Table ISummary of patient clinical dataPatientSexAge, yRelevant medical historyChest x-rayTotal number of days since onset of COVID-19 symptomsDiagnosisMultiplex herpes PCR/SARS-CoV-2 rt-PCR from the vesiclesMedication1 ([Fig 1](#fig1){ref-type="fig"}, *A*)Male69NoneBilateral interstitial pneumonia (required ICU stay)16Recurrent herpes simplex (orolabial)HSV1/negativeHydroxychloroquine, azithromycin, ceftriaxone, acyclovir2Female96Hypertension, chronic kidney disease, hyperuricemiaBilateral interstitial pneumonia27Recurrent herpes simplex (orolabial)HSV1/negativeHydroxychloroquine, azithromycin, prednisone3Female77Primary biliary cholangitis, Alzheimer diseaseBilateral interstitial pneumonia14Recurrent herpes simplex (orolabial)HSV1/not doneHydroxychloroquine, lopinavir/ritonavir, azithromycin, prednisone4Male65Hypertension, dyslipidemiaBilateral interstitial pneumonia (required ICU stay)32Recurrent herpes simplex (orolabial)HSV1/not doneLopinavir/ritonavir, azithromycin, prednisone, tocilizumab, remdesivir, acyclovir5Male38Colorectal cancer (on chemotherapy treatment)Bilateral interstitial pneumonia9Recurrent herpes simplex (orolabial)HSV1/not doneLopinavir/ritonavir, tocilizumab, remdesivir, prednisone, acyclovir6Male61NoneBilateral interstitial pneumonia (required ICU stay)15Recurrent herpes simplex (orolabial)HSV1/not doneHydroxychloroquine, lopinavir/ritonavir, tocilizumab, prednisone, acyclovir7Female45NoneBilateral interstitial pneumonia18Recurrent herpes simplex (orolabial)Not done/not doneHydroxychloroquine8Male76Hypertension, dyslipidemiaBilateral interstitial pneumonia24Recurrent herpes simplex (orolabial)Not done/not doneHydroxychloroquine9 ([Fig 1](#fig1){ref-type="fig"}, *B*)Female56NoneBilateral interstitial pneumonia22Localized herpes zosterHSV3/negativeHydroxychloroquine, valacyclovir11Male52NoneNormal14Localized herpes zosterHSV3/not doneValacyclovir10Female63HypertensionNormal26Localized herpes zoster (ophthalmic)Not done/not doneValacyclovir12Male56dyslipidemiaNormal26Localized herpes zoster (ophthalmic)Not done/not doneValacyclovir13Male82Hypertension, diabetesBilateral interstitial pneumonia7Localized herpes zosterNot done/not doneHydroxychloroquine, acyclovir14Female73DyslipidemiaBilateral interstitial pneumonia12Localized herpes zosterNot done/not doneHydroxychloroquine, prednisone, acyclovir15Male78HypertensionBilateral interstitial pneumonia6Localized herpes zosterNot done/not doneHydroxychloroquine, acyclovir[^1]

Regarding vesicular rashes or varicella-like COVID-19 exanthems,[@bib3] we previously reported 4 cases in which we performed both PCR multiplex for herpesvirus and reverse-transcriptase PCR for SARS-CoV-2 directly from the content of the vesicles. Interestingly, results for both techniques were negative in all 4 cases.[@bib4] This reasonably rules out a role of herpes viruses[@bib3] and a potential infective ability of SARS-CoV-2 through the vesicles.

We agree with the authors that there is a potential role for herpetic viral infections and superinfections in patients with COVID-19. In fact, some presumed COVID-19 vesicular lesions have been later proven to be caused by herpetic infections.[@bib1] ^,^ [@bib5] In our prospective study,[@bib4] from a total of 96 COVID-19 dermatologic consultations in the reported period, 15.6% corresponded to herpes simplex/zoster diagnoses. However, we cannot categorically affirm that there is an incidence increase of these diagnoses in patients with COVID-19 due to the lack of a control group. In our current experience, the diagnosis of herpesvirus infection in patients with COVID-19 does not usually involve diagnostic doubts, due to the clinical presentation and reported symptoms being typical of the disease, even when lesions are extensive ([Fig 1](#fig1){ref-type="fig"} ).Fig 1**A,** A 69-year-old man with COVID-19 pneumonia and extensive orolabial herpes simplex virus 1 reactivation. **B,** A 56-year-old woman with COVID-19 pneumonia and herpes zoster on the trunk.

In conclusion, complementary diagnostic tests for herpesvirus and even SARS-CoV-2 may prove useful for clinical research and should be encouraged if the necessary resources are available. However, we believe that regarding clinical practice, we should reserve these techniques for atypical clinical presentations or cases where therapeutic management would change significantly.
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[^1]: *COVID-19*, Coronavirus disease 2016; *HSV1*, herpes simplex virus 1; *HSV3*, herpes simplex virus 3; *ICU*, intensive care unit; *PCR*, polymerase chain reaction; *rt-PCR*, reverse-transcriptase polymerase chain reaction; *SARS-CoV-2*, severe acute respiratory syndrome coronavirus 2.
